DDInter466 DDInter1676
A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Dactinomycin {u} (Compound) treats {v} (Disease) germ cell cancer
Dactinomycin {u} (Compound) binds {v} (Gene) ABCB1
Dactinomycin {u} (Compound) upregulates {v} (Gene) PRR15L
Dactinomycin {u} (Compound) downregulates {v} (Gene) RNPS1
Dactinomycin {u} (Compound) causes {v} (Side Effect) Discomfort
Dactinomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Dactinomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Dactinomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Dactinomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Dactinomycin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Dactinomycin (Compound) treats germ cell cancer (Disease)
Dactinomycin (Compound) binds ABCB1 (Gene)
Dactinomycin (Compound) upregulates PRR15L (Gene)
Dactinomycin (Compound) downregulates RNPS1 (Gene)
Dactinomycin (Compound) causes Discomfort (Side Effect)
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Dactinomycin may lead to a major life threatening interaction when taken with Leflunomide